Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$534K Buy
2,123
+460
+28% +$99K 0.3% 94
2026
Q1
$362K Sell
1,663
-6
-0.4% -$1.33K 0.25% 114
2025
Q4
$369K Hold
1,669
0.24% 108
2025
Q3
$387K Buy
1,669
+13
+0.8% +$2.65K 0.28% 100
2025
Q2
$313K Sell
1,656
-14
-0.8% -$2.6K 0.26% 97
2025
Q1
$350K Buy
1,670
+7
+0.4% +$1.36K 0.34% 91
2024
Q4
$296K Buy
1,663
+16
+1% +$2.94K 0.28% 97
2024
Q3
$325K Sell
1,647
-1
-0.1% -$187 0.32% 88
2024
Q2
$283K Buy
+1,648
New +$273K 0.3% 92

Other funds holding ABBV

WealthGarden F.S.'s ABBV Position: Q2 2026 in Review

WealthGarden F.S. increased its AbbVie (ABBV) stake by 28% in Q2 2026, buying an estimated $99K and bringing the position to 2,123 shares worth $534K. The position accounts for 0.3% of the portfolio, ranked #94.

WealthGarden F.S. first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • WealthGarden F.S. held 2,123 shares of AbbVie worth $534K as of Q2 2026.
  • WealthGarden F.S. bought 460 AbbVie shares in Q2 2026, an estimated $99K.
  • AbbVie made up 0.3% of WealthGarden F.S.'s portfolio in Q2 2026, its #94 holding.
  • WealthGarden F.S. first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on WealthGarden F.S.'s 13F filing for Q2 2026, filed 31 Jul 2026.